Sign Out
Posology: Individuals from 4 years of age: Qdenga should be administered as a 0.5 mL dose at a two-dose (0 and 3 months) schedule.
The need for a booster dose has not been established.
Other paediatric population (children <4 years of age): The safety and efficacy of Qdenga in children aged less than 4 years has not yet been established. Currently available data are described in Adverse Reactions but no recommendation on a posology can be made.
Elderly: No dose adjustment is required in elderly individuals ≥60 years of age. See Precautions.
Method of administration: After complete reconstitution of the lyophilised vaccine with the solvent, Qdenga should be administered by subcutaneous injection preferably in the upper arm in the region of deltoid.
Qdenga must not be injected intravascularly, intradermally or intramuscularly.
The vaccine should not be mixed in the same syringe with any vaccines or other parenteral medicinal products.
For instructions on reconstitution of Qdenga before administration, see Special precautions for disposal and other handling under Cautions for Usage.
Continue with Google